Cell-free Fetal DNA Testing Market

Spread the love

The Non-invasive Prenatal Testing Global Market Report 2023 by The Business Research Company, provides non-invasive prenatal testing market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten-year historic period – 2010-2021, and a ten-year forecast period – 2023-2032.

Learn More On The Non-invasive Prenatal Testing Market:

https://www.thebusinessresearchcompany.com/report/non-invasive-prenatal-testing-global-market-report

According to The Business Research Company’s Non-invasive Prenatal Testing Global Market Report 2023, the market size will grow from $4.21 billion in 2022 to $4.84 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global non-invasive prenatal testing is expected to grow to $8.36 billion in 2027 at a CAGR of 14.7%.

High incidence rate of Down syndrome is one major factor driving non-invasive prenatal testing market with increase in average maternal age which has led to a concern on the safety about the growth of the fetus. Down syndrome is a chromosomal condition that occurs when an error in cell division results in an extra chromosome 21 and can affect the fetus cognitive ability and physical growth. The NIPT screening tests do not harm the mother or baby, carries no risk of miscarriage as they are non-invasive, and can detect more than 99% of cases of Down syndrome.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=2492&type=smp

The non-invasive prenatal testing market is segmented:

1) By Type: Consumables, Instruments

2) By End User: Hospital, Diagnostic Labs

3) By Instruments: NGS Systems, PCR Instruments, Microarrays, Ultrasound Devices, Others(Centrifuges, UV Systems, Incubators, Microscopes)

4) By Consumables: Assay Kits &Reagents, Disposables

5) By Application: Trisomy, Microdeletion, Genetics, Rh factor

Next-generation sequencing has increased the throughput, scalability, and speed, and further enables researchers to perform a wide range of applications and study biological systems at a higher level. Next-generation sequencing is a platform that has enabled the sequencing of thousands to millions of DNA molecules simultaneously. The manufacturers have introduced this technology to reduce the time and money required and optimizes the output to generate results regarding genome, and DNA testing. Major companies such as Illumina, Eurofins, Natera, Roche, and Annoroad have implemented this technology in non-invasive prenatal testing. CFDA (China Food and Drug Administration) has approved the medical instrument product registration of NGS instrument NextSeq 550AR produced by Annoroad.

The non-invasive prenatal testing market report table of contents includes: